In situ mouse mammary tumor model, administration of STING agonists DMXAA or cGAMP at sites distant from the tumor significantly enhanced the efficacy of Th/Tc17 CAR T cells, which may be related to the upregulation of chemokines CXCL9 and CXCL10 by STING agonists to promote the infiltration of CAR T cells into the tumor tissue. Here, STING1 is linked to breast cancer.